Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

P300/CBP mediated activation of MHCI machinery and IFNg receptor loci controls chemoimmunotherapy

ABSTRACT: p300/CBP mediated activation of MHCI machinery and IFNg receptor loci controls chemoimmunotherapy

PROVIDER: PRJNA636609 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

p300/CBP mediated activation of MHCI machinery and IFNg receptor loci controls chemoimmunotherapy

Project description:Certain chemotherapeutic drugs potentiate responses to immune checkpoint inhibitors (ICI), including PD-(L)1 antibodies, but the mechanisms underlying this synergism are poorly understood. Many cancers evade immune rejection by suppressing MHC-I antigen processing and presentation (AgPP). We show that two classes of DNA damaging drugs, platinoids (e.g. oxaliplatin) and topoisomerase inhibitors (e.g. mitoxanthrone), induce NF-kB activation, nuclear translocation of the histone and lysine acetyl transferases p300/CBP, interferon (IFN) regulatory factors and IFNg receptor 2 (IFNgR2). This results in transcriptional activation of loci coding for the MHC-I transactivator NLRC5 and components of the MHC-I AgPP machinery. Accordingly, p300 inactivation prevents drug-induced upregulation of MHC-I antigen presentation leading to impaired recognition of cancer cells by effector CD8+ T cells, whose tumor rejecting activity is IFNgR2-dependent. Correspondingly, EP300 loss in human cancers correlates with reduced expression of MHC-I related genes and/or changes in neoantigen amount and expression, suggesting that p300 is an immune-directed oncosuppressor.

2021-02-01 | GSE151611 | GEO

Platinoid drugs augment immunotherapy via histone acetylation of MHCI machinery genes [TRAMP]

Project description:Here we show that low dose Oxali, and to a lesser extent other platinoids, can uniquely activate the transcriptional program that controls MHCI antigen processing and presentation. Activation of this program correlates with induction of histone acetylation and enhanced chromatin accessibility. Oxaliplatin also induces NF-kB dependent IFNg receptor 2 (IFNgR2) thereby augmenting the tumor response to exogenous IFNg produced by reinvigorated effector CD8+ T cells.

2021-02-01 | GSE126273 | GEO

Platinoid drugs augment immunotherapy via histone acetylation of MHCI machinery genes [Myc_CaP]

2021-02-01 | GSE126269 | GEO

Platinoid drugs augment immunotherapy via histone acetylation of MHCI machinery genes [AT_MC]

2021-02-01 | GSE126287 | GEO

Platinoid drugs augment immunotherapy via histone acetylation of MHCI machinery genes [CCO19-MC]

2021-02-01 | GSE126274 | GEO

Platinoid drugs augment immunotherapy via histone acetylation of MHCI machinery genes

Project description:Platinoid drugs augment immunotherapy via histone acetylation of MHCI machinery genes

| PRJNA521479 | ENA

Platinoid drugs augment immunotherapy via histone acetylation of MHCI machinery genes [Myc_CaP]

Project description:Platinoid drugs augment immunotherapy via histone acetylation of MHCI machinery genes [Myc_CaP]